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Lack of PMA Effect in the Abnormal Factor X
@actor X Friuti) Coagulation Disorder
A. Gnor.rul" A. D. Mullrn and H. C. Hurlrnn
Laboratories of Cardiovascular Biochemistry and Blood Coagulation Biochemistry'
University Hospital, Leiden
Abstract. Thrombotest dilution curves and specific Key Words
inhibitor experiments were carried out in the abnormal Factor X Friuli
factor X (factor X Friuli) plasma and in coumarin plasma. PfVKA effect
Thrombotest dilution curves obtained with Friuli plasma Coumarin-induced inhibition
suggested the presence of a PfVKAlike inhibitor which Thrombotest
was not confirmed by the specific experiments. The inhi-
bitory capacity found in Friuli plasma was-0.09 arbitrary units, whereas that found in
coumarin-treated patients with a factor X level ranging from I to l{flvaied between
0.34 and 0.21 arbitrary units.
The occurrence of a blood coagulation inhibiting protein in the plasma
ofpatients treated with anticoagulants was first suspected on the observation
that the levels of factors II, VII and X as determined in specific assays did
not correspond to those obtained in the thrombotest system [12, 15]. This
hypothesis was confirmed later on the basis of kinetic experiments. The
action of this protein can be explained by admitting it to act as an analogue
of normal coagulation factors [14]. It was postulated that the inhibitor con-
sists of precursors which cannot be converted into the normal factors be-
cause a final vitamin K-dependent step in their synthesis is blocked. The
existence of such proteins lnduced by vitamin K absence (PIVKAS) was
demonstrated recently by immunological methods [18-20].
The abnormal factor X (factor X Friuli) coagulation disorder was first
described in 1969 and 1970 [4, 5]. This abnormal factor X cannot be activated
or it can be activated only very slowly by partial or whole tissue thrombo-
plastin, whereas it can still be normally activated by Russell's viper venom
U Gnor"ala/Munrn/Hnurrn
(RW). As a consequence factor X results to be low only when assayed using
whole or partial tissue thromboplastin; if factor X is assayed according to
the method of B.q.cHrvraNN et al. [] and DnNsoN [2] it results to be normal or
near normal.
The name 'Friuli' was attached to the conditions since all the patients
originally described to have this disorder came from an isolated valley in the
northeastern Italian region called 'Friuli' [5, 6]. On theoretical grounds, it
could be speculated that this congenitally determined abnormality could
have some similarities with the coumarin-induced abnormal form.
These considerations and the observation of an inhibitory type of
thrombotest dilution curve for the Friuli plasma prompted this report.
Material and Methods
Friuli plasma was obtained in Padova from one of the patients known to have this
disorder (patient M,P.) t5]. The platelet-free citrated plasma was stored in plastic tubes
at -20 "C in 5 ml aliquots and brought to Leiden frozen. In these studies we used plasma
samples drawn on four different dates (16.1 1.1971,14.12.1971,4.2.1972 arld 12.10.1972).
The factor X content in the frozen Friuli plasma as determined in I-eiden with human
brain thromboplastin was 6.8 /" of normal. This was in good agre€ment with the results
obtained in Padova for the same patient on fresh plasma [5, 8]. The mean factor II, factor V
and factor VII levels in frozen Friuli plasma samples were 64.4, 132.2 and 77.81, respec-
tively, in good agreement with the values obtained in Padova on fresh plasma [5], and
within the limits found in plasma from normal persons.
Platelet-free citrated normal plasma was obtained from 30 healthy persons, aged about
30 years, and stored in plastic tubes at -20'C in 10 ml aliquots.
Platelet-free plasma ofan overanticoagulated patient (attempted suicide). The factor X
content in this plasma was about ll of normal, whereas its factor II, V and VII content
was l, 64 and lft, respectively [14].
Human brain thromboplastin, batch 1926 Leiden, was prepared according to a modi-
fication of the method of OwnnN and A-ls [17]. Factor X reagent was prepared as previ-
ously reported [6]. The batch used (batch No. 1110) contained. 0.98 % factor X.
'Fake' Friuli plasma was prepared by mixing 6 parts of normal plasma with 94 parts
of factor X reagent. The factor X content was I 1.0 f, whereas factors II, V, and VII were
22.8, 60.6 and 4I.6 f, respectively.
'Fake' coumarin plnsma was prepared by mixing 99 parts of Al (OH), adsorbed
normal plasma with I part of normal plasma. The factor II, VIL and X content of this
'fake' plasma was l\ of normal.
Thrombotest dilution tests were carried out with 1:1, l:2, L:3, 1:5 and I :10 Michaelis
bufer diluted Friuli plasma, coumarin plasma and normal plasma. Thrombotest reagent
was supplied by Nyegaard Laboratories, Oslo (Batch 123). The investigation of specific
inhibition by Friuli plasma was carried out as previously reported [4]. Normal plasma
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was di luted l :1, l :2, l :3, l :4, l :5, l :6, l :7, l :8,1:9, and l :10 in factor X reagent.
These dilutions were kept in plastic tubes at 0'C. Then to a 0.075-ml aliquot of each of
such dilutions 0,025 ml Friuli plasma or 'fake' Friuli plasma were added, In the case of
counarin plasma or 'fake' coumarin plasma, the volumes were 0.05 ml each. Eventually
factor X was assayed in all mixtures by means of a one-stage method using human brain
tbromboplastin. Clotting times were then plotted against the inverse of factor X concen-
tration. In such a curve a competitive inhibitor causes the straight line giving t" as a func-
tion of u(x) to becomo steeper, maintaining the same interaction with the ordinate.
Thus, the same t-io is read as with the inhibitor present, but a different K- is found.
The inhibitory capacity of the plasma tested can be assessed from the curves obtained
by calculating the ratio K'mjfKm, K- being the Michaelis constant of the uninhibited
series and K'- the apparent Km of the inhibited series'
t-) 
I:-j- :5!" -1, k; being the unknown constant'fu K'- :  K-( l  +-kt,  t  lq  
";This is th€ closest we can get to quantitate ci, i.e. the concentration of the inhibitor'
Results
The results of thrombotest dilution studies are reported in figure 1. The
Friuli plasma dilution curve as well as the coumarin plasma dilution curve
obtained with the (aspecific) thrombotest reagent do not meet the Y-axis at
the same point as the normal plasma dilution curve does' This would seem
to indicate tle presence of an inhibitor and prompted us to try and find in-
hibition in specific experiments where only the concentration of factor X is
varied. Such inhibition can be demonstrated to occur in coumarin plasma
ll4l.
The specific experiments are summarized in table I and II, and in figures 2
and 3. No inhibitory effect seems present in Friuli plasma since the clotting
times obtained at equivalent factor X concentrations are practically identical
to those obtaincd for the 'fake' Friuli plasma (inhibitory capacity: I: -0.09).
On the contrary, in the case of the overanticoagulated plasma, a clear in-
hibitory effect was present. At equivalent factor X concentrations the clotting
times were longer than those obtained for the 'fake' coumarin plasma. These
data are in agreement with the results obtained in other patients given
coumarinlike drugs for therapeutic purposes. In a series of coumarin
plasmas the inhibitory capacity I varied between 0.39 and 0.29 without any
apparent correlation with the concentration of factor X (which varied
between I and l4/).
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These dilutions were kept in plastic tubes at 0 "C. Then to a 0.075-m1 aliquot of each of
such dilutions 0.025 ml Friuli plasma or 'fake' Friuli plasma were added. In the case of
coumarin plasma or'fake' coumarin plasma, the volumes were 0'05 ml each. Eventually
factor X was assayed in all mixtures by means of a one-stage method using human brain
tbromboplastin. Clotting times were then plotted against the inverse of factor X concen-
tration. In such a curve a competitive inhibitor causes the straight line giving t" as a func-
tion of u(x) to become steeper, maintaining the same interaction with the ordinate.
Thus, the same dr;r, is read as with the inhibitor present, but a different K- is found'
The inhibitory capacity of the plasma tested can be assessed from the curves obtained
by calculating the ratio K'-/K-, K- being the Michaelis constant of the uninhibited
series and K'- the apparent K- of the inhibited series.
. . i i K ' .
AsK ' - :  K- (1  +  f . ,  )  I : -  k r  :R*  
-1 ,  k ibe ing theunknownconstan t '
This is the closest we can get to quantitate q, i.e, the concentration of the inhibitor'
Results
The results of thfombotest dilution studies are reported in figure L The
Friuli plasma dilution curve as well as the coumarin plasma dilution curve
obtained with the (aspecific) thrombotest leagent do not meet the Y-axis at
the same point as the normal plasma dilution curve does. This would seem
to indicate the presence of an inhibitor and prompted us to try and find in-
hibition in specific experiments where only the concentration of factor X is
varied. Such inhibition can be demonstrated to occur in coumarin plasma
lt4l .
The specific expefiments are summarized in table I and II, and in figures 2
and 3. No inhibitory effect seems present in Friuli plasma since the clotting
times obtained at equivalent factor X concentrations are practically identical
to those obtained for the 'fake' Friuli plasma (inhibitory capacity: I : -0.09).
on the contrary, in the case of the overanticoagulated plasma, a clear in-
hibitory effect was present. At equivalent factor X concentrations the clotting
times were longer than those obtained for the 'fake' coumarin plasma. These
data are in agreement with the results obtained in other patients given
coumarin-like drugs for therapeutic purposes. In a selies of coumarin
plasmas the inhibitory capacity I varied between 0.39 and 0.29 without any
apparent correlation with the concentration of factor X (which varied
between I and 14l).
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Fig.1. Thrombotest dilution curve with normal plasma, Friuli plasma and coumarin-
treated plasma. The extrapolations of the Friuli plasma and coumarin plasma crrrves to the
Y-axis do not meet with the extrapolation of the normal curve. The coumarin plasma used
in this experiment had a factor X content of l4l, wher€as factor II, V and VII were 21,
100 and 22To,rdspwtively. Using the overanticoagulated plasma" no curve could be con-
structed because of the extremely prolongpd or infinite clotting times obtained'
Fig.2. i,ack of PIVKA effect in Friuli plasma. No difference is evident between Friuli
plasma (o) and 'fake' Friuli plasma ( o). Inhibitory capacitv I : -0.09.
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Frg.3. Behaviour of the overanticoagulated plasma in the specific pIvKA experiment.
At comparable factor X concentrations clotting times are longer in coumarin plasma (o)
as compared to 'fake'coumarin plasma (o). rnhibitory capacity I : 0.39.
Discassion
our data indicate that in Friuli plasma no inhibitory effect is present.
The congenitally abnormal factor X and the abnormal factor X induced by
vitamin K absence do not seem to behave similarly in a coagulation system.
This is the more interesting as there exists a congenital factor II abnormality
(prothrombin Barcelona) which up till now has appeared identical to the
abnormal prothrombin induced by vitamin I( absence [21].
The results of the kinetic studies are in agreement with imnnunological
data [9]. In a cross-over electrophoresis or electrosyneresis system using anti-
human factor X rabbit antiserum it could be demonstrated that coumarin
plasma has two factor X bands [9]. one of these bands is equivalent to the
normal factor X band, the second one, slightly more cathodic to it, is typical
of anticoagulated plasma. In Friuli plasma only an apparently normal
factor X band is visible.
All these data seem to indicate that factor X Friuli is different from the
coumarin-induced abnormal form. The obvious discrepancy between the
thrombotest dilution studies (fig.I) and the specific experiment (fig.2) is
probably due to the fact that in a single factor deficiency or abnormality the
dilution curve approach to the problem is of no value. It is known, in fact,
that factor II, vlr, and IX activities are normal in Friuli plasma [5-7].
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Table I. Clotting times obtained in a specific experiment for Friuli plasma
and 'fake' Friuli plasma
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Table II. Clotting times obtained in a specific experiment for coumarin plasma
and'fake' coumarin plasma
Fake coumarin plasmaCoumarin plasma
dilutions llx clotting time, rlx clotting time,
normal plasma
r lr
u2
u3
u4
us
u6
117
1/8
ue
1i 10
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These observations are also in further agreement with the observation
that the factor X level in Friuli plasma as estimated from the thrombotest
system is practically identical to the level obtained with human brain
thromboplastin, namely 5-10% of normal [8, 11]. The assumption that
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factor X Friuti is a structural, genetically determined factor X abnormality
unaccompanied by the concomitant mutations of factor II, VII, and IX,
andlor by the appearance of a PIVKA-like inhibitor, is further confirmed
by the present study.
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